Table 1.

Clinical characteristics and outcomes

Patient	Age	Follow−up (mo)	FIGO stage	LN status1	Grade	Relapse2	Survival	NF− κB Pre3	NF− κB Post4
1	47	59	IIIA	Pelvic	3	none	Alive	−	−
2	56	16	IIB	Pelvic + PA	2	distant	Alive	−	−
3	40	74	IB2	none	2	none	Alive	−	−
4	36	50	IIB	none	2	none	Dead	−	−
5	53	43	IB2	Pelvic		pelvic	Dead	−	−
6	54	56	IIB	none	2	distant	Alive	−	+
7	49	9	IIB	none	3	paraaortic	Dead	+	−
8	44	76	IIB	none	2	none	Alive	−	+
9	54	79	IIB	none		none	Alive	−	+
10	61	41	IIIB	Pelvic	3	central	Dead	+	−
11	66	34	IIIB	Pelvic + PA	2	distant	Dead	−	+
12	46	32	IIB	Pelvic	3	paraaortic	Dead	−	−
13	30	19	IB2	Pelvic	3	paraaortic	Dead	+	−
14	33	73	IB2	none	2	none	Alive	−	−
15	40	43	IIB	none		none	Alive	−	+
16	28	34	IB2	Pelvic	3	central	Dead	−	−

FIGO, International Federation of Gynecology and Obstetrics

¹CT evidence of pelvic and/or para-aortic (PA) lymph node involvement prior to chemoradiation

²Site of first relapse

³NF-κB expression before treatment initiation

⁴NF-κB expression 2 days after treatment initiation